Pure Energy Minerals Completes Fourth Successful Lithium Brine Pumping Test at Clayton Valley South Project, Nevada
March 27, 2017 09:56 ET
|
Pure Energy Minerals Limited
VANCOUVER, British Columbia, March 27, 2017 (GLOBE NEWSWIRE) -- Pure Energy Minerals Limited (TSX VENTURE:PE) (FRANKFURT:A111EG) (OTCQB:PEMIF) (the “Company” or “Pure Energy”) is pleased to announce...
Pure Energy Minerals Appoints Walter Weinig as Vice President - Projects & Permitting
March 16, 2017 06:30 ET
|
Pure Energy Minerals Limited
VANCOUVER, British Columbia, March 16, 2017 (GLOBE NEWSWIRE) -- Pure Energy Minerals Limited (TSX-V:PE) (FRANKFURT:A111EG) (OTCQB:PEMIF) (the “Company” or “Pure Energy”) is pleased to announce the...
Pure Energy Minerals Closes Purchase Option Agreement on Terra Cotta Project, Argentina
March 09, 2017 08:59 ET
|
Pure Energy Minerals Limited
VANCOUVER, British Columbia, March 09, 2017 (GLOBE NEWSWIRE) -- Pure Energy Minerals Limited (TSX-V:PE) (FRANKFURT:A111EG) (OTCQB:PEMIF) (the “Company” or “Pure Energy”) is pleased to announce that...
McEwen Mining Reports Q3 Production, Mexico Exploration Drill Results
October 13, 2016 06:00 ET
|
McEwen Mining
TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE:MUX) (TSX:MUX) is pleased to announce that total production for the third quarter (“Q3”) was 36,496 gold equivalent ounces using...
A Hemispherx Biopharma anuncia um grande avanco: A aprovacão para comercializar o rintatolimode (nome comercial nos Estados Unidos: Ampligen®) para o tratamento de casos graves de Encefalomielite Miálgica/Síndrome da Fadiga Crônica (EM/SFC) na República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
O primeiro produto aprovado indicado para EM/SFC em qualquer parte do mundo Essa aprovação inédita significa um caminho aberto para o crescimento na América Latina e União Europeia ...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma anuncia un logro importante: aprobación de rintatolimod para la venta comercial (nombre comercial en EE. UU.: Ampligen®) para el tratamiento de casos severos de encefalomielitis miálgica/síndrome de fatiga crónica (EM/SFC) en la República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
Primer producto aprobado para la indicación EM/SFC en todo el mundo Esta nueva aprobación abre paso para el crecimiento en Latinoamérica y la Unión Europea PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 01:00 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 25, 2016 20:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 25, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 24, 2016 10:03 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 24, 2016 (GLOBE...